June 14, 2026

Prostate MRI Results: PI-RADS Score Meaning, Cancer Risk and Do You Need a Biopsy?

Written by
Edward Calleja
Prostate Cancer
Advanced Prostate Cancer
Wave Blue

If you have had a prostate MRI, your report will include a PI-RADS score.

Most men immediately ask:

  • What does my PI-RADS score mean?
  • Do I have prostate cancer?
  • Do I need a biopsy?

The key point is this:

A prostate MRI does not diagnose cancer. It estimates your risk and helps decide what to do next.

A prostate MRI result uses the PI-RADS scoring system (1–5) to estimate cancer risk. Scores 1–2 mean low risk, 3 is uncertain (about 10–20% risk), and 4–5 suggest higher risk (around 40–90%). Whether you need a biopsy depends on PSA density, PSA trends, and overall clinical risk—not MRI alone.

‍

How this applies in real clinical practice

‍

In real-world practice, most men with PI-RADS 3 and low PSA density do not need an immediate biopsy.

The aim is to:

  • Identify the small group of men at higher risk
  • Safely avoid unnecessary procedures in the majority

‍

The goal is not to detect every prostate cancer, but to detect cancers that matter while avoiding unnecessary harm.

‍

What do prostate MRI results actually show?

‍

A prostate MRI is used to:

  • Detect suspicious areas in the prostate
  • Estimate the likelihood of cancer
  • Help decide whether a biopsy is needed

The focus is on detecting clinically significant cancer, meaning cancer that is likely to grow or spread.

‍

PI-RADS score meaning (simple explanation)

‍

PI-RADS (Prostate Imaging Reporting and Data System) is a scoring system used to standardise MRI results.

‍

Each lesion is scored from 1 to 5:

  • PI-RADS 1 → Very low risk (<10%)
  • PI-RADS 2 → Low risk (<10%)
  • PI-RADS 3 → Uncertain risk (~10–20%)
  • PI-RADS 4 → Likely cancer (~40–60%)
  • PI-RADS 5 → Highly likely cancer (~70–90%)

These scores estimate the chance of clinically significant prostate cancer, not just any cancer.

‍

Prostate MRI cancer risk by PI-RADS score

‍

  • PI-RADS 1–2 → Less than 10% risk
  • PI-RADS 3 → 10–20% risk
  • PI-RADS 4 → 40–60% risk
  • PI-RADS 5 → 70–90% risk

These numbers guide decisions but do not confirm cancer.

‍

What should you do after a PI-RADS result?

‍

Use this simple decision rule:

  • PI-RADS 1–2 + low PSA density
    → No biopsy needed

‍

  • PI-RADS 3 + PSA density below 0.15
    → Monitoring is usually safe

‍

  • PI-RADS 3 + PSA density above 0.15
    → Consider biopsy

‍

  • PI-RADS 4–5
    → Biopsy is usually recommended

‍

This reflects modern prostate cancer care.

‍

PSA density explained (the most important number)

‍

PSA density (PSAD) means your PSA level adjusted for the size of your prostate.

It is calculated as:

PSA ÷ prostate volume

This matters because:

  • Larger prostates naturally produce more PSA
  • PSA alone can be misleading

‍

Key threshold:

  • PSA density below 0.15 → lower risk
  • PSA density above 0.15 → higher risk

‍

For a full explanation, read:
Improve Prostate Cancer Detection with PSA Density and MRI PI-RADS
https://www.edwardcalleja.com/blog-posts/improve-prostate-cancer-detection-psa-density-and-mri-pi-rads

‍

What does PI-RADS 3 mean and do you need a biopsy?

‍

PI-RADS 3 is the most uncertain result.

  • Cancer risk is about 10–20%
  • Most men do not have significant cancer

If PSA density is low, monitoring is usually safe.
If PSA density is higher, a biopsy may be needed.

Do you always need a biopsy after an MRI?

No.

Modern practice aims to avoid unnecessary biopsies.

‍

You may not need a biopsy if:

‍

  • PI-RADS 1–2
  • PI-RADS 3 with low PSA density
  • Stable PSA

‍

You are more likely to need a biopsy if:

‍

  • PI-RADS 4 or 5
  • PSA density is high
  • PSA is rising

‍

What happens if you delay a biopsy?

‍

This is a key concern.

‍

In lower-risk situations:

  • Most cancers are slow growing
  • Monitoring allows safe detection if changes occur

‍

In higher-risk situations:

  • Delaying biopsy may delay diagnosis
  • This could affect treatment timing

‍

This is why correct risk assessment is essential.

‍

The biggest mistake after a prostate MRI

‍

Many men assume:
“If the MRI is not clearly cancer, I am safe.”

‍

This is not always true.

  • MRI can miss small cancers
  • PI-RADS 3 is uncertain

‍

The correct approach is: Understand your risk and act accordingly

‍

Can MRI miss prostate cancer?

‍

Yes.

‍

MRI is powerful but not perfect.

  • Some cancers are small or subtle
  • Some benign areas can look suspicious

‍

This is why MRI must be combined with:

  • PSA density
  • Clinical judgement

‍

Read more: MRI Prostate and Its Role in Prostate Cancer Diagnosis
https://www.edwardcalleja.com/blog-posts/mri-prostate-and-role-in-prostate-cancer-diagnosis

‍

Why prostate cancer diagnosis has changed

‍

Previously:

  • Most men with raised PSA had a biopsy

‍

This led to:

  • Unnecessary procedures
  • Detection of low-risk cancers

‍

Today:

  • MRI is done first
  • Decisions are based on risk

‍

This allows:

  • More accurate diagnosis
  • Fewer unnecessary biopsies
  • Better patient outcomes

‍

Key takeaway: PI-RADS is a decision tool

‍

PI-RADS does not diagnose cancer.

It helps decide:

  • Who needs a biopsy
  • Who can safely wait

You are balancing:

  • The risk of missing cancer
  • The risk of unnecessary procedures

‍

FAQ

‍

What does a PI-RADS score mean?

It estimates the likelihood of clinically significant prostate cancer based on MRI findings.

‍

Does PI-RADS 3 mean cancer?

No. It means uncertain risk, with about a 10–20% chance of significant cancer.

‍

Do all PI-RADS 4 or 5 need biopsy?

Most cases do, as cancer risk is high (40–90%).

‍

What is PSA density?

PSA adjusted for prostate size. It is more accurate than PSA alone.

‍

Can MRI replace biopsy?

No. MRI helps decide who needs a biopsy but cannot fully replace it.

‍

Prostate MRI Results Explained: What You Should Do Next

‍

A prostate MRI result is only part of the picture.

‍

The most important factors are:

  • PI-RADS score
  • PSA density
  • PSA trend

The key message is simple: You do not treat the MRI result — you treat the risk.

‍